Prospective, open-label, comparative study on the efficacy of triple (aprepitant + granisetron 3 mg + dexamethasone) versus double (palonosetron 0.75 mg + dexamethasone) combination therapy for nausea and vomiting during moderately emetogenic chemotherapy containing carboplatin: CAP Study - CAP study

Kyushu Medical Center Clinical Research Institute0 个研究点目标入组 200 人开始时间: 2013年3月7日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Patients with serious hepatopathy or nephropathy. 2)Patients suffering from nausea or vomiting within 24 hours before the start of chemotherapy. 3)Patients receiving antiemetic drugs within 24 hours before the start of chemotherapy. 4)Patients with emetogenic factors other than chemotherapy (such as brain tumor, gastrointestinal obstruction, active peptic ulcer, and brain metastasis). 5)Patients who have received radiation therapy or are scheduled to receive it to the abdominal region or pelvis within 1 week before or after the start of the study. 6)Patients with concomitant diseases that make 3-day dexamethasone therapy impossible, such as uncontrolled diabetes mellitus. 7)Pregnant women, women who wish to become pregnant, and breast-feeding women. 8)Patients on treatment with pimozide. 9)Other patients whom the investigator considers to be unfit for enrollment in the study.

发起方

Kyushu Medical Center Clinical Research Institute